Temat: "Antineoplastic Agents" - OpacWWW

Starter badań:

Antineoplastics in chemotherapy.

Anticancer drugs used to treat malignancies and cancerous growths.

Salem Press Encyclopedia of Health, 2019. 3p.

Skocz do pozycji: 1 1.

Tytuł :: Combinatorial Effect of Temozolomide and Naringenin in Human Glioblastoma Multiforme Cell Lines.
Autorzy :: Gautam M; Department of Biotechnology, Jaypee Institute of Information Technology, Noida, Uttar Pradesh, India.
Gabrani R; Department of Biotechnology, Jaypee Institute of Information Technology, Noida, Uttar Pradesh, India.; Pokaż więcej
Źródło :: Nutrition and cancer [Nutr Cancer] 2022; Vol. 74 (3), pp. 1071-1078. Date of Electronic Publication: 2021 Aug 25.
Typ publikacji :: Journal Article
MeSH Terms :: Antineoplastic Agents*/pharmacology
Brain Neoplasms*/pathology
Flavanones*/pharmacology
Glioblastoma*/pathology
Antineoplastic Agents, Alkylating/pharmacology ; Apoptosis ; Cell Line, Tumor ; Drug Resistance, Neoplasm ; Humans ; Temozolomide/pharmacology
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 2 2.

Tytuł :: Pharmacotranscriptomic profiling of resistant triple-negative breast cancer cells treated with lapatinib and berberine shows upregulation of PI3K/Akt signaling under cytotoxic stress.
Autorzy :: Jabbarzadeh Kaboli P; Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou 646000, Sichuan, PR China; Graduate Institute of Biomedical Sciences, Research Center for Cancer Biology, and Center for Molecular Medicine, China Medical University, Taichung, Taiwan, ROC. Electronic address: .
Luo S; Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou 646000, Sichuan, PR China.
Chen Y; Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou 646000, Sichuan, PR China; South Sichuan Institution for Translational Medicine, Luzhou 646000, Sichuan, PR China.
Jomhori M; Department of Biotechnology Research, Razi Vaccine and Serum Research Institute, Mashhad, Iran.
Imani S; Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou 646000, Sichuan, PR China.
Xiang S; Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou 646000, Sichuan, PR China; South Sichuan Institution for Translational Medicine, Luzhou 646000, Sichuan, PR China.
Wu Z; Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou 646000, Sichuan, PR China; South Sichuan Institution for Translational Medicine, Luzhou 646000, Sichuan, PR China; Department of Pharmacy, The Affiliated Hospital of Southwest Medical University, Luzhou 646000, Sichuan, PR China.
Li M; Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou 646000, Sichuan, PR China; South Sichuan Institution for Translational Medicine, Luzhou 646000, Sichuan, PR China.
Shen J; Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou 646000, Sichuan, PR China; South Sichuan Institution for Translational Medicine, Luzhou 646000, Sichuan, PR China.
Zhao Y; Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou 646000, Sichuan, PR China; South Sichuan Institution for Translational Medicine, Luzhou 646000, Sichuan, PR China.
Wu X; Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou 646000, Sichuan, PR China; South Sichuan Institution for Translational Medicine, Luzhou 646000, Sichuan, PR China.
Hin Cho C; Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou 646000, Sichuan, PR China; South Sichuan Institution for Translational Medicine, Luzhou 646000, Sichuan, PR China.
Xiao Z; Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou 646000, Sichuan, PR China; South Sichuan Institution for Translational Medicine, Luzhou 646000, Sichuan, PR China. Electronic address: .; Pokaż więcej
Źródło :: Gene [Gene] 2022 Mar 30; Vol. 816, pp. 146171. Date of Electronic Publication: 2022 Jan 10.
Typ publikacji :: Journal Article
MeSH Terms :: Antineoplastic Agents/*pharmacology
Berberine/*pharmacology
Lapatinib/*pharmacology
Protein Kinase Inhibitors/*pharmacology
Proto-Oncogene Proteins c-akt/*metabolism
Triple Negative Breast Neoplasms/*drug therapy
Antineoplastic Agents, Phytogenic/pharmacology ; Cell Cycle/drug effects ; Cell Line, Tumor ; Cyclin-Dependent Kinase 6/metabolism ; DNA (Cytosine-5-)-Methyltransferase 1/metabolism ; Epigenesis, Genetic ; ErbB Receptors/metabolism ; Gene Expression Regulation, Neoplastic/drug effects ; Genes, myc ; Humans ; Proto-Oncogene Proteins c-akt/antagonists & inhibitors ; Proto-Oncogene Proteins p21(ras)/metabolism ; Pyrimidines/pharmacology ; Pyrroles/pharmacology ; Signal Transduction/drug effects ; Transcriptome/drug effects ; Triple Negative Breast Neoplasms/metabolism ; Up-Regulation/drug effects
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 3 3.

Tytuł :: Pharmacological profile and effects of mitotane in adrenocortical carcinoma.
Autorzy :: Corso CR; Instituto de Pesquisa Pelé Pequeno Príncipe, Curitiba, Brazil.; Faculdades Pequeno Príncipe, Curitiba, Brazil.
Acco A; Pharmacology Department, Federal University of Paraná, Curitiba, Brazil.
Bach C; Instituto de Pesquisa Pelé Pequeno Príncipe, Curitiba, Brazil.; Faculdades Pequeno Príncipe, Curitiba, Brazil.
Bonatto SJR; Instituto de Pesquisa Pelé Pequeno Príncipe, Curitiba, Brazil.; Faculdades Pequeno Príncipe, Curitiba, Brazil.
de Figueiredo BC; Instituto de Pesquisa Pelé Pequeno Príncipe, Curitiba, Brazil.; Faculdades Pequeno Príncipe, Curitiba, Brazil.
de Souza LM; Instituto de Pesquisa Pelé Pequeno Príncipe, Curitiba, Brazil.; Faculdades Pequeno Príncipe, Curitiba, Brazil.; Pokaż więcej
Źródło :: British journal of clinical pharmacology [Br J Clin Pharmacol] 2021 Jul; Vol. 87 (7), pp. 2698-2710. Date of Electronic Publication: 2021 Feb 02.
Typ publikacji :: Journal Article; Research Support, Non-U.S. Gov't; Review
MeSH Terms :: Adrenal Cortex Neoplasms*/drug therapy
Adrenocortical Carcinoma*/drug therapy
Antineoplastic Agents*/therapeutic use
Antineoplastic Agents, Hormonal/pharmacology ; Antineoplastic Agents, Hormonal/therapeutic use ; Humans ; Mitotane/therapeutic use ; Steroids
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 4 4.

Tytuł :: The potential role of vitamin C in empowering cancer immunotherapy.
Autorzy :: Bedhiafi T; Translational Cancer Research Facility, Translational Research Institute, Hamad Medical Corporation, Doha, Qatar.
Inchakalody VP; Translational Cancer Research Facility, Translational Research Institute, Hamad Medical Corporation, Doha, Qatar; National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar.
Fernandes Q; Translational Cancer Research Facility, Translational Research Institute, Hamad Medical Corporation, Doha, Qatar; College of Medicine, Qatar University, Doha, Qatar.
Mestiri S; Translational Cancer Research Facility, Translational Research Institute, Hamad Medical Corporation, Doha, Qatar.
Billa N; College of Pharmacy, Qatar University, Doha, Qatar.
Uddin S; Translational Research Institute and dermatology Institute, Academic Health System, Hamad Medical Corporation, Doha, Qatar; Laboratory Animal Research Center, Qatar University, Doha 2713, Qatar.
Merhi M; Translational Cancer Research Facility, Translational Research Institute, Hamad Medical Corporation, Doha, Qatar; National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar. Electronic address: .
Dermime S; Translational Cancer Research Facility, Translational Research Institute, Hamad Medical Corporation, Doha, Qatar; National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar; College of Health and Life Sciences, Hamad Bin Khalifa University, Doha, Qatar. Electronic address: .; Pokaż więcej
Źródło :: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie [Biomed Pharmacother] 2022 Feb; Vol. 146, pp. 112553. Date of Electronic Publication: 2021 Dec 20.
Typ publikacji :: Journal Article; Review
MeSH Terms :: Antineoplastic Agents/*pharmacology
Ascorbic Acid/*pharmacology
Neoplasms/*drug therapy
Animals ; Antineoplastic Agents/therapeutic use ; Antineoplastic Agents, Immunological/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Ascorbic Acid/therapeutic use ; Cell Line, Tumor ; Cell Survival/drug effects ; Cytokines/drug effects ; Dose-Response Relationship, Drug ; Drug Resistance, Neoplasm/drug effects ; Epigenesis, Genetic/drug effects ; Humans ; Immune Checkpoint Inhibitors/pharmacology ; Immune Checkpoint Inhibitors/therapeutic use ; Neoplasms/physiopathology ; Oxidative Stress/drug effects ; T-Lymphocytes/drug effects ; Tumor Microenvironment/drug effects
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 5 5.

Tytuł :: Current Treatment of Chronic Lymphocytic Leukemia: The Diminishing Role of Chemoimmunotherapy.
Autorzy :: Roeker LE; Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY, 10021, USA. .
Thompson M; Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY, 10021, USA.
Mato AR; Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY, 10021, USA.; Pokaż więcej
Źródło :: Drugs [Drugs] 2022 Feb; Vol. 82 (2), pp. 133-143. Date of Electronic Publication: 2021 Dec 21.
Typ publikacji :: Journal Article; Review
MeSH Terms :: Antineoplastic Agents, Immunological/*therapeutic use
Leukemia, Lymphocytic, Chronic, B-Cell/*drug therapy
Agammaglobulinaemia Tyrosine Kinase/antagonists & inhibitors ; Antineoplastic Agents/therapeutic use ; Antineoplastic Agents, Immunological/administration & dosage ; Antineoplastic Agents, Immunological/adverse effects ; Antineoplastic Agents, Immunological/pharmacology ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Humans ; Leukemia, Lymphocytic, Chronic, B-Cell/pathology ; Phosphoinositide-3 Kinase Inhibitors/therapeutic use ; Proto-Oncogene Proteins/antagonists & inhibitors ; Randomized Controlled Trials as Topic ; Recurrence
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 6 6.

Tytuł :: [Administrative delays of temporary recommendation for use: Impact on access to innovation in melanoma].
Autorzy :: Auger C; Centre hospitalier de Voiron, 38500 Voiron, France.
Guillot B; Université de Montpellier, faculté de médecine, 34000 Montpellier, France.
Monard A; Institut Daniel Hollard, Avec groupe hospitalier mutualiste de Grenoble, 8, rue Dr Calmette, 38000 Grenoble cedex 1, France.
Albin N; Institut Daniel Hollard, Avec groupe hospitalier mutualiste de Grenoble, 8, rue Dr Calmette, 38000 Grenoble cedex 1, France. Electronic address: .; Pokaż więcej
Transliterated Title :: Délais administratifs des RTU, effet sur l’accès à l’innovation dans le mélanome.
Źródło :: Bulletin du cancer [Bull Cancer] 2022 Jan; Vol. 109 (1), pp. 28-37. Date of Electronic Publication: 2021 Dec 28.
Typ publikacji :: Journal Article
MeSH Terms :: Antineoplastic Agents/*supply & distribution
Drug Approval/*legislation & jurisprudence
Melanoma/*drug therapy
Skin Neoplasms/*drug therapy
Adult ; Antibodies, Monoclonal, Humanized/economics ; Antibodies, Monoclonal, Humanized/therapeutic use ; Antineoplastic Agents/economics ; Antineoplastic Agents/therapeutic use ; Antineoplastic Agents, Immunological/economics ; Antineoplastic Agents, Immunological/supply & distribution ; Antineoplastic Agents, Immunological/therapeutic use ; Chemotherapy, Adjuvant ; Clinical Trials as Topic ; Decision Making ; Drug Combinations ; France ; Humans ; Imidazoles/economics ; Imidazoles/supply & distribution ; Imidazoles/therapeutic use ; Insurance, Health, Reimbursement ; Ipilimumab/therapeutic use ; Neoplasm Recurrence, Local/prevention & control ; Nivolumab/economics ; Nivolumab/therapeutic use ; Oximes/economics ; Oximes/supply & distribution ; Oximes/therapeutic use ; Pyridones/economics ; Pyridones/supply & distribution ; Pyridones/therapeutic use ; Pyrimidinones/economics ; Pyrimidinones/supply & distribution ; Pyrimidinones/therapeutic use
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 7 7.

Tytuł :: Current Advancements of Plant-Derived Agents for Triple-Negative Breast Cancer Therapy through Deregulating Cancer Cell Functions and Reprogramming Tumor Microenvironment.
Autorzy :: Wu TN; Agricultural Biotechnology Research Center, Academia Sinica, Taipei 115, Taiwan.
Chen HM; Agricultural Biotechnology Research Center, Academia Sinica, Taipei 115, Taiwan.
Shyur LF; Agricultural Biotechnology Research Center, Academia Sinica, Taipei 115, Taiwan.; Ph.D. Program in Translational Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan.; Graduate Institute of Pharmacognosy, Taipei Medical University, Taipei 110, Taiwan.; Pokaż więcej
Źródło :: International journal of molecular sciences [Int J Mol Sci] 2021 Dec 17; Vol. 22 (24). Date of Electronic Publication: 2021 Dec 17.
Typ publikacji :: Journal Article; Review
MeSH Terms :: Antineoplastic Agents, Phytogenic/*therapeutic use
Triple Negative Breast Neoplasms/*drug therapy
Tumor Microenvironment/*drug effects
Animals ; Antineoplastic Agents, Immunological/pharmacology ; Antineoplastic Agents, Immunological/therapeutic use ; Antineoplastic Agents, Phytogenic/pharmacology ; Drug Development ; Female ; Humans ; Triple Negative Breast Neoplasms/immunology ; Triple Negative Breast Neoplasms/pathology ; Tumor Escape/drug effects
: Czasopismo naukowe

Szczegóły Pełny tekst Pełny tekst

Skocz do pozycji: 8 8.

Tytuł :: Avelumab as neoadjuvant therapy in patients with urothelial non-metastatic muscle invasive bladder cancer: a multicenter, randomized, non-comparative, phase II study (Oncodistinct 004 - AURA trial).
Autorzy :: Martinez Chanza N; Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium. .; Hopital Erasme, Université Libre de Bruxelles, Brussels, Belgium. .
Soukane L; Hopital Erasme, Université Libre de Bruxelles, Brussels, Belgium.
Barthelemy P; Institut de Cancérologie Strasbourg Europe ICANS, Strasbourg, France.
Carnot A; Centre Oscar Lambret, Lille, France.
Gil T; Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium.
Casert V; Centre Hospitalier Universitaire de Ambrois Paré, Mons, Belgium.
Vanhaudenarde V; Clinique Sainte-Elisabeth, UCL, Namur, Belgium.
Sautois B; University Hospital of Liege (CHU Sart Tilman), Liège, Belgium.
Staudacher L; Hopital Paris Saint Joseph, Paris, France.
Van den Brande J; University Hospital Antwerp, UZA, Antwerp, Belgium.
Culine S; Hopital Saint-Louis, Paris, France.
Seront E; Hopital de Jolimont, Jolimont, Belgium.
Gizzi M; Grand Hopital de Charleroi, Charleroi, Belgium.
Albisinni S; Hopital Erasme, Université Libre de Bruxelles, Brussels, Belgium.
Tricard T; Institut de Cancérologie Strasbourg Europe ICANS, Strasbourg, France.
Fantoni JC; Centre Oscar Lambret, Lille, France.
Paesmans M; Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium.
Caparica R; Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium.
Roumeguere T; Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium.; Hopital Erasme, Université Libre de Bruxelles, Brussels, Belgium.
Awada A; Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium.; Pokaż więcej
Źródło :: BMC cancer [BMC Cancer] 2021 Dec 02; Vol. 21 (1), pp. 1292. Date of Electronic Publication: 2021 Dec 02.
Typ publikacji :: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial
MeSH Terms :: Antibodies, Monoclonal, Humanized/*therapeutic use
Antineoplastic Agents, Immunological/*therapeutic use
Immune Checkpoint Inhibitors/*therapeutic use
Neoadjuvant Therapy/*methods
Urinary Bladder Neoplasms/*drug therapy
Antibodies, Monoclonal, Humanized/adverse effects ; Antineoplastic Agents/therapeutic use ; Antineoplastic Agents, Immunological/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Chemotherapy, Adjuvant/methods ; Cisplatin/administration & dosage ; Cisplatin/therapeutic use ; Deoxycytidine/administration & dosage ; Deoxycytidine/analogs & derivatives ; Deoxycytidine/therapeutic use ; Doxorubicin/administration & dosage ; Doxorubicin/therapeutic use ; Humans ; Methotrexate/administration & dosage ; Methotrexate/therapeutic use ; Paclitaxel/administration & dosage ; Paclitaxel/therapeutic use ; Urinary Bladder Neoplasms/pathology ; Vinblastine/administration & dosage ; Vinblastine/therapeutic use
SCR Protocol :: M-VAC protocol
: Czasopismo naukowe

Szczegóły Pełny tekst

Skocz do pozycji: 9 9.

Tytuł :: Synergistic effect of the anti-PD-1 antibody with blood stable and reduction sensitive curcumin micelles on colon cancer.
Autorzy :: Gong F; Key Laboratory for Ultrafine Materials of Ministry of Education, School of Materials Science and Engineering, East China University of Science and Technology, Shanghai, China.
Ma JC; Department of Cell Biology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China.; Guangdong Provincial Key Laboratory of Bone and Joint Degeneration Diseases, The Third Affiliated Hospital, Southern Medical University, Guangzhou, China.
Jia J; Department of Cardiology, Shanghai Institute of Cardiovascular Disease, Zhongshan Hospital, Fudan University, Shanghai, China.
Li FZ; Department of Cell Biology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China.
Wu JL; Department of Cell Biology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China.
Wang S; School of Materials Science and Engineering, Sun Yat-sen University, Guangzhou, China.
Teng X; Key Laboratory for Ultrafine Materials of Ministry of Education, School of Materials Science and Engineering, East China University of Science and Technology, Shanghai, China.
Cui ZK; Department of Cell Biology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China.; Guangdong Provincial Key Laboratory of Bone and Joint Degeneration Diseases, The Third Affiliated Hospital, Southern Medical University, Guangzhou, China.; Pokaż więcej
Źródło :: Drug delivery [Drug Deliv] 2021 Dec; Vol. 28 (1), pp. 930-942.
Typ publikacji :: Journal Article
MeSH Terms :: Micelles*
Antineoplastic Agents/*pharmacokinetics
Colonic Neoplasms/*drug therapy
Curcumin/*pharmacokinetics
Programmed Cell Death 1 Receptor/*antagonists & inhibitors
Animals ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents, Immunological ; Cell Line ; Cell Line, Tumor ; Chemistry, Pharmaceutical ; Curcumin/administration & dosage ; Delayed-Action Preparations ; Drug Carriers ; Drug Liberation ; Drug Stability ; Drug Synergism ; Female ; Hemolysis ; Humans ; Male ; Mice ; Mice, Inbred C57BL ; Nanoparticles ; Random Allocation ; Rats ; Rats, Sprague-Dawley ; Xenograft Model Antitumor Assays
: Czasopismo naukowe

Szczegóły Pełny tekst

Skocz do pozycji: 10 10.

Tytuł :: Risk-tailored treatment of splenic marginal zone lymphoma.
Autorzy :: Castelli R; Università degli studi di Sassari, scienze mediche chirurgiche e sperimentali.
Balzarotti M; Medical Oncology and Hematology Unit, Humanitas Clinical and Research Center - IRCCS, Humanitas Cancer Center, Rozzano.
Salvi E; Department of Biomedical and Clinical Sciences Luigi Sacco, University of Milan.
Simona Rossi R; Service of Pathology, ASST Fatebenefratelli-Sacco, Luigi Sacco, University Hospital Milano.
Lambertenghi Deliliers G; Fondazione Mattarelli, Milan, Italy and UO e Dipartimento di Medicina Interna IRCCS Istituto Auxologico Italiano, Italy.
Bergamaschini L; Department of Biomedical and Clinical Sciences Luigi Sacco, University of Milan.
Gidaro A; Department of Biomedical and Clinical Sciences Luigi Sacco, University of Milan.; Pokaż więcej
Źródło :: Anti-cancer drugs [Anticancer Drugs] 2022 Jan 01; Vol. 33 (1), pp. e36-e42.
Typ publikacji :: Journal Article; Review
MeSH Terms :: Antineoplastic Agents, Immunological/*therapeutic use
Lymphoma, B-Cell, Marginal Zone/*drug therapy
Lymphoma, B-Cell, Marginal Zone/*pathology
Precision Medicine/*methods
Splenic Neoplasms/*drug therapy
Splenic Neoplasms/*pathology
Antineoplastic Agents/therapeutic use ; Disease Progression ; Hepatitis B/pathology ; Hepatitis C/epidemiology ; Hepatitis C/pathology ; Humans ; Lymphoma, B-Cell, Marginal Zone/epidemiology ; Lymphoma, B-Cell, Marginal Zone/surgery ; Lymphoma, Large B-Cell, Diffuse/physiopathology ; NF-kappa B/metabolism ; Neoplasm Staging ; Receptor, Notch2/genetics ; Receptor, Notch2/metabolism ; Receptors, Antigen, B-Cell/genetics ; Receptors, Antigen, B-Cell/immunology ; Risk Assessment ; Risk Factors ; Signal Transduction ; Splenectomy ; Splenic Neoplasms/epidemiology ; Splenic Neoplasms/surgery ; Tumor Microenvironment/physiology
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 11 11.

Tytuł :: Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update.
Autorzy :: Burstein HJ; Dana Farber Cancer Institute, Boston, MA.
Somerfield MR; American Society of Clinical Oncology, Alexandria, VA.
Barton DL; University of Michigan School of Nursing, Ann Arbor, MI.
Dorris A; Lobular Breast Cancer Research Advocate, San Francisco, CA.
Fallowfield LJ; University of Sussex, Brighton, United Kingdom.
Jain D; Houston Methodist Hospital and Health Care, Houston, TX.
Johnston SRD; Royal Marsden NHS Foundation Trust, London, United Kingdom.
Korde LA; Clinical Investigations Branch, CTEP, DCTD, National Cancer Institute, Bethesda, MD.
Litton JK; University of Texas MD Anderson Cancer Center, Houston, TX.
Macrae ER; Columbus Oncology Associates, Columbus, OH.
Peterson LL; Division of Medical Oncology, Washington University School of Medicine, Saint Louis, MO.
Vikas P; University of Iowa Holden Comprehensive Cancer Center, Iowa City, IA.
Yung RL; University of Washington, Seattle, WA.
Rugo HS; University of California San Francisco Comprehensive Cancer Center, San Francisco, CA.; Pokaż więcej
Źródło :: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2021 Dec 10; Vol. 39 (35), pp. 3959-3977. Date of Electronic Publication: 2021 Jul 29.
Typ publikacji :: Journal Article; Meta-Analysis; Systematic Review
MeSH Terms :: Antineoplastic Agents, Hormonal/*therapeutic use
Biomarkers, Tumor/*metabolism
Breast Neoplasms/*drug therapy
Practice Guidelines as Topic/*standards
Receptor, ErbB-2/*metabolism
Receptors, Estrogen/*metabolism
Receptors, Progesterone/*metabolism
Antineoplastic Agents/therapeutic use ; Biomarkers, Tumor/genetics ; Breast Neoplasms/metabolism ; Breast Neoplasms/pathology ; Female ; Humans ; Molecular Targeted Therapy ; Prognosis
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 12 12.

Tytuł :: Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update.
Autorzy :: Moy B; Massachusetts General Hospital, Boston, MA.
Rumble RB; American Society of Clinical Oncology, Alexandria, VA.
Come SE; Beth Israel Deaconess Medical Center, Boston, MA.
Davidson NE; Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA.
Di Leo A; Hospital of Prato, Istituto Toscano Tumori, Prato, Italy.; Deceased.
Gralow JR; University of Washington, Seattle, WA.
Hortobagyi GN; MD Anderson Cancer Center, Houston, TX.
Yee D; University of Minnesota, Minneapolis and Saint Paul, MN.
Smith IE; Royal Marsden Hospital, London, United Kingdom.
Chavez-MacGregor M; MD Anderson Cancer Center, Houston, TX.
Nanda R; University of Chicago, Chicago, IL.
McArthur HL; Cedars-Sinai, Los Angeles, CA.
Spring L; Massachusetts General Hospital, Boston, MA.
Reeder-Hayes KE; UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC.
Ruddy KJ; Mayo Clinic, Rochester, MN.
Unger PS; University of Vermont Health Network, Burlington, VT.
Vinayak S; Seattle Cancer Care Alliance and University of Washington, Seattle, WA.
Irvin WJ Jr; Bon Secours St Francis, Midlothian, VA.
Armaghani A; Moffitt Cancer Center, Tampa, FL.
Danso MA; Virginia Oncology Associates, Norfolk, VA.
Dickson N; Tennessee Oncology, Nashville, TN.
Turner SS; Patient Representative, New York, NY.
Perkins CL; Patient Representative, Dallas, TX.
Carey LA; UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC.; Pokaż więcej
Źródło :: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2021 Dec 10; Vol. 39 (35), pp. 3938-3958. Date of Electronic Publication: 2021 Jul 29.
Typ publikacji :: Journal Article; Meta-Analysis; Systematic Review
MeSH Terms :: Antineoplastic Agents, Hormonal/*therapeutic use
Poly(ADP-ribose) Polymerase Inhibitors/*therapeutic use
Practice Guidelines as Topic/*standards
Receptor, ErbB-2/*metabolism
Receptors, Estrogen/*metabolism
Receptors, Progesterone/*metabolism
Triple Negative Breast Neoplasms/*drug therapy
Antineoplastic Agents/therapeutic use ; Female ; Humans ; Molecular Targeted Therapy ; Prognosis ; Triple Negative Breast Neoplasms/metabolism ; Triple Negative Breast Neoplasms/pathology
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 13 13.

Tytuł :: Prognostic value of TP53 expression and MGMT methylation in glioblastoma patients treated with temozolomide combined with other chemotherapies.
Autorzy :: Kurdi M; Department of Pathology, Faculty of Medicine in Rabigh, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia. .
Butt NS; Department of Family and Community Medicine, Faculty of Medicine in Rabigh, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia.
Baeesa S; Division of Neurosurgery, Faculty of Medicine, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia.
Alghamdi B; Department of Physiology, Faculty of Medicine, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia.
Maghrabi Y; Department of Neuroscience, King Faisal Specialist Hospital and Research Center, Jeddah, Kingdom of Saudi Arabia.
Bardeesi A; Department of Neuroscience, King Faisal Specialist Hospital and Research Center, Jeddah, Kingdom of Saudi Arabia.
Saeedi R; Division of Neurosurgery, Faculty of Medicine, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia.
Dallol A; Center of Excellence in Genomic Medicine Research, Faculty of Applied Medical Science, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia.
Mohamed F; Department of Pathology, Faculty of Medicine in Rabigh, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia.
Bari MO; Department of Pathology, King Abdulaziz University Hospital, Jeddah, Kingdom of Saudi Arabia.
Samkari A; Department of Pathology and Laboratory Medicine, King Saud Bin Abdulaziz University for Health Science, Jeddah, Kingdom of Saudi Arabia.
Lary AI; Section of Neurosurgery, Department of Surgery, King Abdulaziz Medical City, Jeddah, Kingdom of Saudi Arabia.
Alkhayyat S; Division of Oncology, Faculty of Medicine, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia.; Pokaż więcej
Źródło :: Journal of neuro-oncology [J Neurooncol] 2021 May; Vol. 152 (3), pp. 541-549. Date of Electronic Publication: 2021 Mar 04.
Typ publikacji :: Journal Article
MeSH Terms :: Antineoplastic Agents*/therapeutic use
Brain Neoplasms*/drug therapy
Brain Neoplasms*/genetics
Glioblastoma*/drug therapy
Glioblastoma*/genetics
Antineoplastic Agents, Alkylating/therapeutic use ; DNA Methylation ; DNA Modification Methylases ; DNA Repair Enzymes/genetics ; Dacarbazine/therapeutic use ; Humans ; O(6)-Methylguanine-DNA Methyltransferase/genetics ; Prognosis ; Temozolomide/therapeutic use ; Tumor Suppressor Protein p53/genetics ; Tumor Suppressor Proteins
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 14 14.

Tytuł :: Treatment of liver cancer cells with ethyl acetate extract of Crithmum maritimum permits reducing sorafenib dose and toxicity maintaining its efficacy.
Autorzy :: Gnocchi D; Interdisciplinary Department of Medicine, University of Bari School of Medicine, Bari, Italy.
Castellaneta F; Interdisciplinary Department of Medicine, University of Bari School of Medicine, Bari, Italy.
Cesari G; International Centre for Advanced Mediterranean Agronomic Studies - CHIEAM, Valenzano (BA), Italy.
Fiore G; Interdisciplinary Department of Medicine, University of Bari School of Medicine, Bari, Italy.
Sabbà C; Interdisciplinary Department of Medicine, University of Bari School of Medicine, Bari, Italy.
Mazzocca A; Interdisciplinary Department of Medicine, University of Bari School of Medicine, Bari, Italy.; Pokaż więcej
Źródło :: The Journal of pharmacy and pharmacology [J Pharm Pharmacol] 2021 Sep 07; Vol. 73 (10), pp. 1369-1376.
Typ publikacji :: Journal Article
MeSH Terms :: Apiaceae*
Phytotherapy*
Antineoplastic Agents, Phytogenic/*therapeutic use
Carcinoma, Hepatocellular/*drug therapy
Liver Neoplasms/*drug therapy
Plant Extracts/*therapeutic use
Sorafenib/*administration & dosage
Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/pharmacology ; Antineoplastic Agents/therapeutic use ; Antineoplastic Agents, Phytogenic/pharmacology ; Apoptosis ; Cell Cycle Checkpoints/drug effects ; Cell Line, Tumor ; Cell Proliferation ; Drug Synergism ; Hep G2 Cells ; Humans ; Inhibitory Concentration 50 ; Liver/drug effects ; Plant Extracts/pharmacology ; Sorafenib/pharmacology ; Sorafenib/therapeutic use
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 15 15.

Tytuł :: Impact of COVID-19 Pandemic on Surgical Breast Cancer Patients Undergoing Neoadjuvant Therapy: A Multicentric Study.
Autorzy :: Vanni G; Breast Unit, Department of Surgical Science, Policlinico Tor Vergata University, Rome, Italy.
Pellicciaro M; Breast Unit, Department of Surgical Science, Policlinico Tor Vergata University, Rome, Italy; .
Combi F; Division of Breast Surgical Oncology Department of Medical and Surgery, Maternal-infantile and Adult Sciences, University Hospital of Modena and Reggio Emilila, Modena, Italy.
Papi S; Division of Breast Surgical Oncology Department of Medical and Surgery, Maternal-infantile and Adult Sciences, University Hospital of Modena and Reggio Emilila, Modena, Italy.
Materazzo M; Breast Unit, Department of Surgical Science, Policlinico Tor Vergata University, Rome, Italy.
Segattini S; Division of Breast Surgical Oncology Department of Medical and Surgery, Maternal-infantile and Adult Sciences, University Hospital of Modena and Reggio Emilila, Modena, Italy.
Rizza S; Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
Chiocchi M; Department of Diagnostic Imaging, Molecular Imaging, Interventional Radiology and Radiotherapy, University of Rome, Rome, Italy.
Perretta T; Department of Diagnostic Imaging, Molecular Imaging, Interventional Radiology and Radiotherapy, University of Rome, Rome, Italy.
Meucci R; Department of Diagnostic Imaging, Molecular Imaging, Interventional Radiology and Radiotherapy, University of Rome, Rome, Italy.
Portarena I; Department of Oncology, Policlinico Tor Vergata University, Rome, Italy.
Pistolese CA; Department of Diagnostic Imaging, Molecular Imaging, Interventional Radiology and Radiotherapy, University of Rome, Rome, Italy.
Ielpo B; Unidad de Chirugia Hepatobiliopancreática, Hospital Universitario del Mar, Barcelona, Spain.
Campanelli M; Emergency Surgery Unit, University Hospital of Tor Vergata, Rome, Italy.
Lisi G; Department of Surgery, Sant'Eugenio Hospital, Rome, Italy.
Chiaravalloti A; Department of Biomedicine and Prevention, Policlinico Tor Vergata University, Rome, Italy.; IRCCS Neuromed, UOC Medicina Nucleare, Pozzilli, Italy.
Tazzioli G; Division of Breast Surgical Oncology Department of Medical and Surgery, Maternal-infantile and Adult Sciences, University Hospital of Modena and Reggio Emilila, Modena, Italy.
Buonomo OC; Breast Unit, Department of Surgical Science, Policlinico Tor Vergata University, Rome, Italy.; Pokaż więcej
Źródło :: Anticancer research [Anticancer Res] 2021 Sep; Vol. 41 (9), pp. 4535-4542.
Typ publikacji :: Comparative Study; Journal Article; Multicenter Study
MeSH Terms :: Antineoplastic Agents/*administration & dosage
Breast Neoplasms/*drug therapy
Breast Neoplasms/*surgery
COVID-19/*epidemiology
Mammaplasty/*statistics & numerical data
Neoadjuvant Therapy/*statistics & numerical data
Adult ; Aged ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents, Hormonal/administration & dosage ; Antineoplastic Agents, Hormonal/adverse effects ; COVID-19/complications ; Drug Therapy/statistics & numerical data ; Female ; Humans ; Middle Aged ; Neoadjuvant Therapy/adverse effects ; Pandemics ; Retrospective Studies ; Treatment Outcome
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 16 16.

Tytuł :: Study on potential antineoplastic effect of matrine in gastric carcinoma via inhibiting VEGF.
Autorzy :: Shen X; Department of Gastrointestinal Surgery, Affiliated Hospital of Jiangnan University, Wuxi Third People's Hospital, Wuxi, China.
Bao C; Department of Gastrointestinal Surgery, Affiliated Hospital of Jiangnan University, Wuxi Third People's Hospital, Wuxi, China - .; Pokaż więcej
Źródło :: Panminerva medica [Panminerva Med] 2021 Sep; Vol. 63 (3), pp. 381. Date of Electronic Publication: 2019 Jul 26.
Typ publikacji :: Journal Article
MeSH Terms :: Alkaloids/*pharmacology
Antineoplastic Agents/*therapeutic use
Carcinoma/*drug therapy
Quinolizines/*pharmacology
Stomach Neoplasms/*drug therapy
Vascular Endothelial Growth Factor A/*drug effects
Alkaloids/therapeutic use ; Antineoplastic Agents/pharmacology ; Antineoplastic Agents, Phytogenic/pharmacology ; Apoptosis/drug effects ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Humans ; Quinolizines/therapeutic use
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 17 17.

Tytuł :: Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial.
Autorzy :: Aggarwal C; Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA .
Prawira A; Kinghorn Cancer Centre, St. Vincent's Hospital, Sydney, New South Wales, Australia.
Antonia S; Duke Cancer Institute Center for Cancer Immunotherapy, Durham, North Carolina, USA.; Moffitt Cancer Center, Tampa, Florida, USA.
Rahma O; Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Tolcher A; NEXT Oncology, San Antonio, Texas, USA.; START-South Texas, San Antonio, Texas, USA.
Cohen RB; Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Lou Y; Mayo Clinic, Jacksonville, Florida, USA.
Hauke R; Nebraska Cancer Specialists, Omaha, Nebraska, USA.
Vogelzang N; Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, USA.
P Zandberg D; UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.; University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, USA.
Kalebasty AR; Norton Cancer Institute, Louisville, Kentucky, USA.
Atkinson V; Princess Alexandra Hospital, Woolloongabba, Queensland, Australia.
Adjei AA; Mayo Clinic, Rochester, Minnesota, USA.
Seetharam M; Mayo Clinic, Scottsdale, Arizona, USA.
Birnbaum A; Rhode Island Hospital, Providence, Rhode Island, USA.
Weickhardt A; Austin Health, Heidelberg, Victoria, Australia.
Ganju V; Peninsula and Southeast Oncology, Frankston, Victoria, Australia.
Joshua AM; Kinghorn Cancer Centre, St. Vincent's Hospital, Sydney, New South Wales, Australia.
Cavallo R; MacroGenics, Inc, Rockville, Maryland, USA.
Peng L; MacroGenics, Inc, Rockville, Maryland, USA.
Zhang X; MacroGenics, Inc, Rockville, Maryland, USA.
Kaul S; AstraZeneca, Gaithersburg, Maryland, USA.
Baughman J; MacroGenics, Inc, Rockville, Maryland, USA.
Bonvini E; MacroGenics, Inc, Rockville, Maryland, USA.
Moore PA; MacroGenics, Inc, Rockville, Maryland, USA.
Goldberg SM; MacroGenics, Inc, Rockville, Maryland, USA.
Arnaldez FI; MacroGenics, Inc, Rockville, Maryland, USA.; AstraZeneca, Gaithersburg, Maryland, USA.
Ferris RL; UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
Lakhani NJ; START Midwest, Grand Rapids, Michigan, USA.; Pokaż więcej
Źródło :: Journal for immunotherapy of cancer [J Immunother Cancer] 2022 Apr; Vol. 10 (4).
Typ publikacji :: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study
MeSH Terms :: Antineoplastic Agents*/therapeutic use
Antineoplastic Agents, Immunological*/adverse effects
Carcinoma, Non-Small-Cell Lung*/drug therapy
Head and Neck Neoplasms*/drug therapy
Lung Neoplasms*/pathology
Antibodies, Monoclonal/therapeutic use ; Antibodies, Monoclonal, Humanized ; B7 Antigens ; Humans ; Programmed Cell Death 1 Receptor ; Squamous Cell Carcinoma of Head and Neck/drug therapy
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 18 18.

Tytuł :: Three New Aglain Derivatives from Aglaia odorata Lour. and Their Cytotoxic Activities.
Autorzy :: Wu PF; State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, 550014, P. R. China.; The Key Laboratory of Chemistry for Natural Products of Guizhou Province and Chinese Academy of Sciences, Guiyang, 550014, P. R. China.
Liu J; Graduate School, Guizhou Medical University, University Town, Guian New District, Guiyang, 550025, P. R. China.
Li YN; State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, 550014, P. R. China.; The Key Laboratory of Chemistry for Natural Products of Guizhou Province and Chinese Academy of Sciences, Guiyang, 550014, P. R. China.
Ding R; State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, 550014, P. R. China.; The Key Laboratory of Chemistry for Natural Products of Guizhou Province and Chinese Academy of Sciences, Guiyang, 550014, P. R. China.
Tan R; Pharmacy Affiliated Hospital of Guizhou Medical University, Guiyang, 550001, P. R. China.
Yang XM; State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, 550014, P. R. China.; The Key Laboratory of Chemistry for Natural Products of Guizhou Province and Chinese Academy of Sciences, Guiyang, 550014, P. R. China.
Yu Y; State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, 550014, P. R. China.; The Key Laboratory of Chemistry for Natural Products of Guizhou Province and Chinese Academy of Sciences, Guiyang, 550014, P. R. China.
Hao XJ; State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, 550014, P. R. China.; The Key Laboratory of Chemistry for Natural Products of Guizhou Province and Chinese Academy of Sciences, Guiyang, 550014, P. R. China.
Yuan CM; State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, 550014, P. R. China.; The Key Laboratory of Chemistry for Natural Products of Guizhou Province and Chinese Academy of Sciences, Guiyang, 550014, P. R. China.
Yi P; State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, 550014, P. R. China.; The Key Laboratory of Chemistry for Natural Products of Guizhou Province and Chinese Academy of Sciences, Guiyang, 550014, P. R. China.; Pokaż więcej
Źródło :: Chemistry & biodiversity [Chem Biodivers] 2022 Apr; Vol. 19 (4), pp. e202101008. Date of Electronic Publication: 2022 Mar 08.
Typ publikacji :: Journal Article
MeSH Terms :: Aglaia*/chemistry
Antineoplastic Agents*/pharmacology
Antineoplastic Agents, Phytogenic*/chemistry
Antineoplastic Agents, Phytogenic*/pharmacology
Triterpenes*/chemistry
Circular Dichroism ; Humans ; Molecular Structure ; Plant Extracts/chemistry
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 19 19.

Tytuł :: Discovery of Potential Neuroprotective Agents against Paclitaxel-Induced Peripheral Neuropathy.
Autorzy :: Chen YF; Department of Pharmacology, College of Medicine, National Cheng Kung University, Tainan City 70101, Taiwan, R. O. C.; Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan City 70101, Taiwan, R. O. C.
Wu CH; Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli County 35053, Taiwan, R. O. C.
Chen LH; Department of Pharmacology, College of Medicine, National Cheng Kung University, Tainan City 70101, Taiwan, R. O. C.
Lee HW; Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli County 35053, Taiwan, R. O. C.
Lee JC; Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli County 35053, Taiwan, R. O. C.
Yeh TK; Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli County 35053, Taiwan, R. O. C.
Chang JY; Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli County 35053, Taiwan, R. O. C.
Chou MC; Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli County 35053, Taiwan, R. O. C.
Wu HL; Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli County 35053, Taiwan, R. O. C.
Lai YP; Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli County 35053, Taiwan, R. O. C.
Song JS; Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli County 35053, Taiwan, R. O. C.
Yeh KC; Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli County 35053, Taiwan, R. O. C.
Chen CT; Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli County 35053, Taiwan, R. O. C.
Lee CJ; Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli County 35053, Taiwan, R. O. C.
Shia KS; Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli County 35053, Taiwan, R. O. C.
Shen MR; Department of Pharmacology, College of Medicine, National Cheng Kung University, Tainan City 70101, Taiwan, R. O. C.; Department of Obstetrics & Gynecology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan City 70101, Taiwan, R. O. C.; Pokaż więcej
Źródło :: Journal of medicinal chemistry [J Med Chem] 2022 Mar 24; Vol. 65 (6), pp. 4767-4782. Date of Electronic Publication: 2022 Mar 02.
Typ publikacji :: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :: Antineoplastic Agents*/pharmacology
Antineoplastic Agents, Phytogenic*/toxicity
Neuroprotective Agents*/pharmacology
Neuroprotective Agents*/therapeutic use
Peripheral Nervous System Diseases*/chemically induced
Peripheral Nervous System Diseases*/drug therapy
Peripheral Nervous System Diseases*/prevention & control
Animals ; Ganglia, Spinal ; Mice ; Paclitaxel/toxicity
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 20 20.

Tytuł :: Plants in Anticancer Drug Discovery: From Molecular Mechanism to Chemoprevention.
Autorzy :: Siddiqui AJ; Department of Biology, College of Science, University of Hail, Hail, PO Box 2440, Saudi Arabia.
Jahan S; Department of Medical Laboratory Sciences, College of Applied Medical Sciences, Majmaah University, Al-Majmaah 11952, Saudi Arabia.
Singh R; Department of Environmental Sciences, School of Earth Sciences, Central University of Rajasthan, Ajmer, India.
Saxena J; Faculty of Applied Sciences and Biotechnology, Shoolini University of Biotechnology and Management Sciences, Bajhol, Solan, Himachal Pradesh, India.; Department of Biotechnology, University Institute of Biotechnology, Chandigarh University, Gharuan, NH-95, 140413, Ludhiana-Chandigarh State Hwy, Punjab, India.
Ashraf SA; Department of Clinical Nutrition, College of Applied Medical Sciences, University of Hail, Hail, PO Box 2440, Saudi Arabia.
Khan A; Department of Pharmacology and Toxicology, College of Pharmacy, Jazan University, Jazan 45142, Saudi Arabia.
Choudhary RK; Department of Medical Laboratory Sciences, College of Applied Medical Sciences, Majmaah University, Al-Majmaah 11952, Saudi Arabia.
Balakrishnan S; Department of Medical Equipment Technology, College of Applied Medical Sciences, Majmaah University, Al Majmaah 11952, Saudi Arabia.; Department of Biomedical Engineering, Velalar College of Engineering and Technology, Erode, 638012 Tamil Nadu, India.
Badraoui R; Department of Biology, College of Science, University of Hail, Hail, PO Box 2440, Saudi Arabia.
Bardakci F; Department of Biology, College of Science, University of Hail, Hail, PO Box 2440, Saudi Arabia.
Adnan M; Department of Biology, College of Science, University of Hail, Hail, PO Box 2440, Saudi Arabia.; Pokaż więcej
Źródło :: BioMed research international [Biomed Res Int] 2022 Mar 02; Vol. 2022, pp. 5425485. Date of Electronic Publication: 2022 Mar 02 (Print Publication: 2022).
Typ publikacji :: Journal Article; Review
MeSH Terms :: Antineoplastic Agents*/pharmacology
Antineoplastic Agents*/therapeutic use
Antineoplastic Agents, Phytogenic*/therapeutic use
Neoplasms*/drug therapy
Neoplasms*/prevention & control
Plants, Medicinal*
Chemoprevention ; Drug Discovery ; Humans
: Czasopismo naukowe

Szczegóły Pełny tekst Pełny tekst

Informacja

Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Antineoplastic Agents"" wg kryterium: Temat

Źródło danych

Ogranicz do:

Ogranicz do bazy

Typ dokumentu

Temat

Wydawca

Publikacja

Język

Starter badań:

Antineoplastics in chemotherapy.